[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"itp---immune-thrombocytopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:itp---immune-thrombocytopenia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,81,109,133,157,183,203,224,251,276,298],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100643933","phase-2-tpo-ra-plus-baricitinib-vs-tpo-ra-for-itp-100643933",false,"NCT07669675","TPO-RA Plus Baricitinib vs. TPO-RA for ITP","TPO-RA Plus Baricitinib vs. TPO-RA in Patients With ITP : A Randomized, Open-label Trial","Inclusion Criteria:\n\n1. ≥18 years old;\n2. Patients diagnosed with primary ITP who failed to achieve a response after 14 days of full-dose TPO-RA therapy;\n3. Patients with baseline platelet count less than 30×10⁹\u002FL, or those with baseline platelet count ranging from 30×10⁹\u002FL to 50×10⁹\u002FL accompanied by clinically significant bleeding (WHO bleeding score ≥2).\n\nExclusion Criteria:\n\n* Pregnant or lactating women, and who were possibly pregnant, planning to become pregnant, or who had partners planning to become pregnant;\n* With active malignancy or a history of malignant tumor;\n* Having experienced severe bacterial, viral, fungal or parasitic infection within the past 4 weeks;\n* With a history of symptomatic herpes zoster infection within 12 weeks prior to screening;\n* Active or chronic HBV, HCV or HIV infection;\n* Evidence of active tuberculosis; or previous evidence of active tuberculosis without appropriate and documented treatment; or household contact with patients with active tuberculosis without appropriate and documented tuberculosis prophylaxis;\n* Receipt of live vaccines within the past 12 weeks, or planned live vaccination during the study period;\n* Prior baricitinib therapy;\n* History of solid organ transplant or planned surgery;\n* Myelodysplastic syndrome, aplastic anemia or myelofibrosis;\n* Patients with other diseases were undergoing treatment with immunosuppressants;\n* Clinically significant thromboembolic events within the past 24 weeks, or ongoing anticoagulant treatment, who are deemed ineligible for the study by the investigator;\n* History or presence of myocardial infarction, unstable ischemic heart disease, stroke, or NYHA Class IV heart failure;\n* History or active manifestations of severe or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, neurological, neuropsychiatric, or other medical conditions that, in the investigator's judgment, could confer unacceptable safety risks with the investigational product or confound the interpretation of study data;\n* AST \\> 2 times the upper limit of normal (ULN), ALT \\> 2×ULN, TBIL ≥ 1.5×ULN;\n* eGFR \\\u003C 50 mL\u002Fmin\u002F1.73m²;\n* Other patients deemed unsuitable for enrollment in this study by the investigator.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a prospective, randomized, controlled trial. ITP patients who failed prior full-does TPO-RA monotheray for 14 days. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone. The primary endpoint was the 14-day overall response rate without any rescue therapy.",[26],"ITP - Immune Thrombocytopenia",[28,29,30],"immune thrombocytopenia","baricitinib","TPO-RA","NOT_YET_RECRUITING","2026-06-20",{"date":34,"type":35},"2026-06-25","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2028-08-31",{"name":41,"class":42},"Peking University People's Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100635208","phase-1-safety-and-preliminary-efficacy-of-ctx112-in-adult-participants-with-relapsedrefractory-hematologic-autoimmune-disease-100635208","NCT07549698","Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed\u002FRefractory Hematologic Autoimmune Disease","A Phase 1\u002F2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed\u002FRefractory Hematologic Autoimmune Disease","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Participants must voluntarily sign a written informed consent and be willing and able to comply with all trial requirements.\n3. Adequate hematologic, renal, liver, cardiac and pulmonary function.\n4. Participants must agree to use acceptable methods of contraception.\n5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other trial procedures.\n6. Diagnosis of relapsed\u002Frefractory primary Immune Thrombocytopenic Purpura (ITP) or Warm Autoimmune Hemolytic Anemia (WAIHA)\n\nExclusion Criteria:\n\n1. Prior treatment with anti-CD19 therapy or any gene therapy or genetically modified cell therapy.\n2. Prior solid organ (e.g., heart, liver, kidney, lung) transplant or hematopoietic cell transplant.\n3. Severe active or history of central nervous (CNS) involvement.\n4. Presence of other active autoimmune disease or other conditions that are likely to pose increased safety risks and\u002For confound disease assessments, or pose significant risk to those receiving CAR T cell therapy.\n5. History of primary or secondary immunodeficiency.\n6. Presence or history of certain bacterial, viral or fungal infection\n7. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).\n8. Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome.\n9. History or current diagnosis that requires uninterrupted, ongoing anticoagulation.\n10. Pregnant or lactating.\n11. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.",{"count":51,"type":20},60,[53,23],"PHASE1","This is a single-arm, open-label, multicenter, ascending dose Phase 1\u002F2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed\u002Frefractory primary Immune Thrombocytopenia (ITP) and relapsed\u002Frefractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).",[56,26,57,58],"Warm Autoimmune Hemolytic Anemia (WAIHA)","Warm Autoimmune Hemolytic Anemia","Immune Thrombocytopenic Purpura",[60,61,62,63,64,65,66,67,58,68],"CD19","CTX112","Zugocabtagene geleucel","zugo-cel","CAR-T","ITP","warm autoimmune hemolytic anemia","wAIHA","Immune Thrombocytopenia","RECRUITING","2026-06-11",{"date":72,"type":35},"2026-06-15",{"date":74,"type":20},"2026-06",{"date":76,"type":20},"2033-12",{"name":78,"class":79},"CRISPR Therapeutics AG","INDUSTRY",3,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100607922","phase-2-a-study-of-efgartigimod-iv-in-participants-from-12-years-to-less-than-18-years-of-age-with-chronic-immune-thrombocytopenia-itp-100607922","NCT07194850","A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)","A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP","Inclusion Criteria:\n\n* Is aged 12 to less than 18 years when completing the informed consent process\n* Has a documented duration of primary ITP of more than 12 months on the date the informed consent process is complete\n* Has documented prior ITP treatment with at least 1 of the following treatments: corticosteroids, IVIg, anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RAs), or rituximab.\n* Has documented prior response, defined as 1 platelet count of ≥50 × 10\\^9\u002FL to at least 1 of the following ITP treatments: prednisone, other or nonspecified corticosteroids, IVIg, or anti-D immunoglobulin\n* Has documented insufficient response to a prior ITP treatment with corticosteroids, IVIg, anti-D immunoglobulin, TPO-RAs, rituximab, or splenectomy\n* Has documented mean platelet count of less than 30 x10\\^9\u002FL\n\nExclusion Criteria:\n\n* Secondary ITP according to the following definition by the International Working Group (IWG): all forms of immune-mediated thrombocytopenia except primary ITP\n* Nonimmune thrombocytopenia\n* ITP-associated critical or severe bleeding\n* History of hereditary thrombocytopenia","12 Years","17 Years",{"count":91,"type":20},24,[23,93],"PHASE3","The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).\n\nThe study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second year (OLTP2). After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks.\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Fadvancejunior",[96,26,65,58,97,98,99],"Immune Thrombocytopenia (ITP)","Immune Thrombocytopenic Purpura ( ITP )","Idiopathic Thrombocytopenic Purpura","Idiopathic Thrombocytopenic Purpura (ITP)",{"date":101,"type":35},"2026-06-12",{"date":103,"type":35},"2025-10-20",{"date":105,"type":20},"2030-10",{"name":107,"class":79},"argenx",10,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100614385","phase-2-avatrombopag-combined-with-all-trans-retinoic-acid-in-the-treatment-of-primary-immune-thrombocytopenia-100614385","NCT07278908","Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia","Efficacy and Safety of Avatrombopag Versus Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia: a Multicenter, Open-label, Randomized Controlled Study","Inclusion Criteria:\n\n1. The patient signs an informed consent form;\n2. ≥ 18 years old;\n3. The patient's history of ITP is at least 3 months (persistent or chronic ITP);\n4. The platelet count of the subject within 24 hours before the first administration of the study drug is less than 30 × 10\\^9\u002FL; during the screening period, platelet count is measured at least twice (at least 1 week apart), with an average platelet count of less than 30 × 10\\^9\u002FL and no platelet count greater than 35 × 10\\^9\u002FL;\n5. First line treatment, such as ineffective hormone or immunoglobulin therapy, or ITP patients who relapse after treatment;\n6. Receive concomitant therapy drugs (including stable doses of glucocorticoids within the past month, stable doses of azathioprine, danazol, cyclosporine A, or mycophenolate mofetil within the past three months) for treatment; TPO receptor agonists should be discontinued at least 2 weeks before enrollment; Patients receiving anti-CD20 treatment should discontinue the medication six months prior to enrollment; Patients who underwent splenectomy were enrolled six months after the completion of the surgery;\n7. Within the past year, there have been no heart diseases, including NYHA class III\u002FIV congestive heart failure, drug-induced arrhythmias, or myocardial infarction;\n8. Laboratory tests of coagulation function showed that the prothrombin time (PT\u002FINR) and activated partial thromboplastin time (APTT) values did not exceed 20% of the normal reference range; No history of coagulation abnormalities except for ITP;\n9. White blood cell count, absolute neutrophil count, and hemoglobin are within the normal range in the laboratory, with no abnormalities other than ITP, except for the following situations: a) Hemoglobin: If the anemia is clearly caused by iron deficiency anemia (excessive loss of blood related to thrombocytopenia) due to ITP, the subject's hemoglobin level below the lower limit of normal values can be selected for the study based on the researcher's judgment; c) Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL can be included in the group;\n10. The main organ function is good, that is, the liver and kidney function is good before treatment, AST and ALT are ≤ 1.5 times the upper limit of normal (ULN), total bilirubin is ≤ 1.5 times ULN, and serum creatinine is ≤ 1.5 times ULN;\n11. The subjects adopted approved contraceptive methods. Female participants must be infertile (hysterectomy, bilateral salpingectomy, bilateral tubal ligation, or more than 1 year after menopause) or have the ability to conceive but have used study approved contraceptive methods during the entire study period until the end of the follow-up period, 2 weeks before the first dose; Women with fertility must have a negative serum pregnancy test within 24 hours prior to the first dose of medication;\n12. The subjects fully understand and are able to comply with the requirements of the research protocol, and are willing to complete the study as planned.\n\nExclusion Criteria:\n\n1. Individuals who are allergic to known ingredients or excipients in atorvastatin or all trans retinoic acid;\n2. Accept medication maintenance therapy (including but not limited to aspirin, clopidogrel, and\u002For nonsteroidal anti-inflammatory drugs NSAIDs) or anticoagulants that affect platelet function or quantity;\n3. Accompanied by autoimmune hemolytic anemia, or various secondary or hereditary thrombocytopenia; Such as leukemia, lymphoma, multiple myeloma, aplastic anemia, myelodysplastic syndrome, Evans syndrome, common variant immunodeficiency, systemic lupus erythematosus, cirrhosis, antiphospholipid antibody syndrome, pseudothrombocytopenia, drug-induced thrombocytopenia (such as quinine, heparin, antimicrobial drugs, antiepileptic drugs, etc.), etc;\n4. There is bone marrow fibrosis with MF ≥ 2;\n5. Participate in other research drug studies (including vaccine studies) or be exposed to other research drugs (TPO receptor agonists or salvage treatments) within 4 weeks or 5 half lives (whichever is longer) before the first use of the medication;\n6. Previous ITP treatments, including rescue therapy with platelet transfusions, glucocorticoids, immunoglobulins, immunomodulators, etc., did not end within 2 weeks prior to enrollment;\n7. The subject has a history of any arterial\u002Fvenous thrombosis (including stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, or pulmonary embolism) within the past year;\n8. Pregnant or lactating women;\n9. History of alcohol\u002Fdrug abuse within 12 months prior to screening or first dose;\n10. Previous studies have shown poor efficacy in the treatment of sufficient and sufficient doses of atorvastatin;\n11. Previous all trans retinoic acid had poor efficacy;\n12. All laboratory or clinical evidence of HIV infection and active hepatitis during screening. Laboratory tests during the screening period indicate active hepatitis C infection or hepatitis B infection. (hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU\u002Fml; Hepatitis C reference: HCV antibody positive and HCV virus copy number\\>upper limit of normal);\n13. Life threatening bleeding (WHO bleeding score 3) or estimated need for salvage treatment before the first dose of treatment in patients;\n14. History of malignant tumors or accompanying malignant tumors;\n15. The researchers believe that there are any other circumstances that may prevent the subjects from completing the study or pose significant risks to them.",{"count":117,"type":20},248,[23,93],"This study is an open label, randomized controlled, multicenter clinical trial aimed at comparing the efficacy and safety of the combination of atorvastatin and all trans retinoic acid with atorvastatin alone in the treatment of first-line ineffective or recurrent immune thrombocytopenia.\n\nThe study is divided into a screening period (2 weeks), a treatment period (0-24 weeks), a reduction period (25-36 weeks), and a follow-up period (37-52 weeks), with a total of one year from the start of treatment to the end of follow-up (52 weeks).",[26],[68,122,123],"all trans retinoic acid","Avatrombopag","2025-12-09",{"date":126,"type":35},"2025-12-12",{"date":128,"type":20},"2025-12",{"date":130,"type":20},"2028-12",{"name":132,"class":42},"Institute of Hematology & Blood Diseases Hospital, China",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":80},"100599397","phase-1-om336-in-autoimmune-cytopenias-100599397","NCT07083960","OM336 in Autoimmune Cytopenias","An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias","Key Inclusion Criteria:\n\n* Active autoimmune cytopenia\n* Relapsed\u002Frefractory after ≥1 prior treatment\n* Body weight ≥ 55 kg\n* Willing to comply with and study requirements and procedures\n\nKey Exclusion Criteria:\n\n* Previous treatment with a BCMA-targeted therapy\n* Clinically significant infection within 3 months of screening\n* Major surgery or splenectomy within 3 months of screening or planned during the study\n* Pregnant or breastfeeding","75 Years",{"count":142,"type":20},32,[53],"An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.",[146,147,26],"AIHA - Warm Autoimmune Hemolytic Anemia","AIHA - Cold Autoimmune Hemolytic Anemia","2025-09-24",{"date":150,"type":35},"2025-09-30",{"date":152,"type":35},"2025-08-01",{"date":154,"type":20},"2027-09",{"name":156,"class":79},"Ouro Medicines",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100603218","phase-4-exploring-the-efficacy-safety-of-a-modified-starting-dosage-of-avatrombopag-in-immune-throbocytopenia-itp---a-pilot-study-100603218","NCT07133659","Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study","Ava dosing","Inclusion Criteria:\n\n1. Male or female aged ≥18 years.\n2. Diagnosis of primary ITP and having a platelet count of \\\u003C 30 x109\u002FL measured within two weeks prior to inclusion with failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone \u002Fprednisolone (1 mg\u002Fkg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects.\n3. Clinical need for second (subsequent) line treatment with a platelet elevating therapy assessed by the physician in charge.\n4. Signed and dated written informed consent.\n\nExclusion Criteria:\n\n1. Previous treatment with TPO-RA.\n2. Pregnancy or lactation.\n3. Patients with active serious bleeding or at high risk of bleeding as judged by physician in charge.\n4. Females of child-bearing potential refusing to follow effective contraceptive methods (as described in SmPC) during treatment with Avatrombopag.\n5. Secondary ITP defined as ITP secondary to lymphoma or chronic lymphocytic leukemia; ITP secondary to the following autoimmune disorders Systemic Lupus Erythematosus or Antiphospholipid Syndrome; ITP secondary to Common Variable Immune Deficiency; ITP secondary to the following viral infections eg Human Immunodeficiency Virus.\n6. Concomitant autoimmune hemolytic anemia, Evans syndrome.\n7. Presence of any serious comorbidity where the condition may worsen the study drugs.\n8. Presence of active malignancy unless deemed cured by adequate treatment. Participants with the following neoplastic conditions can be included:\n\n   * Monoclonal gammopathy of undetermined significance (MGUS) or monoclonal B lymphocytosis of undetermined significance (MBUS)\n   * Basal\u002Fsquamous cell carcinoma of the skin\n   * Carcinoma in situ of the cervix\n   * Carcinoma in situ of the breast\n   * Incidental histological finding of prostate cancer (TNM stage T1a or T1b)\n9. Patients with history of poor compliance or history of alcohol\u002Fdrug abuse or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.\n\n   \\-",{"count":165,"type":20},25,[167],"PHASE4","This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag",[26],[65,171,123,172],"thrombocytopenia","thrombopoietin receptor agonist","2025-08-14",{"date":175,"type":35},"2025-08-21",{"date":177,"type":35},"2025-06-08",{"date":179,"type":20},"2027-07-08",{"name":181,"class":42},"Al-Mustansiriyah University",1,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":182},"100600139","eltrombopag-induced-liver-dysfunction-during-treatment-of-immunethrombocytopenic-purpura-100600139","NCT07093606","Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura","Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver\n\nExclusion Criteria:\n\nPre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.",{"count":19,"type":20},[191],"NA","this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.",[26],"2025-07-23",{"date":196,"type":35},"2025-07-30",{"date":198,"type":35},"2025-07-14",{"date":200,"type":20},"2026-01-20",{"name":202,"class":42},"Sohag University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":65,"eligibilityCriteria":208,"healthyVolunteers":209,"sex":16,"minAge":210,"maxAge":17,"enrollmentInfo":211,"targetDuration":4,"studyType":213,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100594089","cytotoxic-t-lymphocyte-associated-antigen-4-ctla-4-gene-single-nucleotide-polymorphism-in-primary-immune-thrombocytopenic-purpura-in-children-100594089","NCT07014904","\"Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children\"","Inclusion criteria: approval to sign an informed written consent, patient with newly diagnosed ITP, patient age \\> 1 year and \\\u003C 18 years and both sexes are included.\n\nExclusion criteria:\n\nRefusal to sign an informed written consent, patient with persistent ITP, patient with chronic ITP, patient with secondary immune thrombocytopenia and patient age \\\u003C 1 year or \\> 18 years",true,"1 Year",{"count":212,"type":20},80,"OBSERVATIONAL","the investigators aim in this study to investigate the potential association of single gene polymorphisms of CTLA-4 (SNPs; rs: 3087243) using real-time PCR in children with primary ITP.",[26],"2025-06-12",{"date":218,"type":35},"2025-06-17",{"date":220,"type":20},"2025-08-20",{"date":222,"type":20},"2027-07-20",{"name":202,"class":42},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":231,"maxAge":4,"enrollmentInfo":232,"targetDuration":210,"studyType":213,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":250},"100586743","resti-registry-spanish-registry-of-primary-immune-thrombocytopenia-and-other-immune-thrombocytopenia-100586743","NCT06919341","RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia","RESTI","Inclusion Criteria:\n\n* Children as young as 2 months of age and adults in follow-up since 2015 (irrespective of date of diagnosis) with the diagnostic presumption of PIT or other thrombocytopenia of probable immune origin defined as a platelet count \\\u003C 100 x 109\u002FL.\n* Patients who have given written informed consent. In the case of deceased patients, the data will be included in the registry and the investigator will record the impossibility of collecting patient's informed consent form due to death. Only patients deceased after December 31 2015, will be included\n\nExclusion Criteria:\n\n* Patients who, at the investigator's discretion, do not meet the conditions for inclusion in the study","2 Months",{"count":233,"type":20},1000,"Primary immune thrombocytopenia (PIT), previously referred to as idiopathic thrombocytopenic purpura, is an acquired disease characterized by accelerated platelet destruction and deficient platelet production by megakaryocytes.\n\nAlthough the existence of PIT has been known for decades, there is no consensus on its triggering mechanisms. On the other hand, this disease presents a very heterogeneous patient profile, both in its characteristics and treatments. In this sense, the diagnosis is still made by excluding other causes of thrombocytopenia.\n\nThere is insufficient epidemiological data on the disease, a fact that is especially evident in our country. We have no data on the incidence or prevalence of this pathology in Spain.\n\nFor all these reasons, this epidemiological study has been designed to increase the available knowledge about this disease and the detailed characterization of the population of patients with ITP in Spain.\n\nThe main objective of this study is to describe the clinical, analytical and treatment characteristics of primary immune thrombocytopenia and other immune thrombocytopenia.\n\nThe study is an epidemiological, ambispective, multicenter study carried out in hospitals in Spain.\n\nInformation will be collected on the disease under study, as well as on the treatments received, using the patient's clinical history as a source document.",[26,236],"Primary Immune Thrombocytopenia (ITP)",[65,238,239,240],"PTI","Trombocitopenia inmune primaria","Primary Inmune Thrombocytopenia","2025-04-07",{"date":243,"type":35},"2025-04-09",{"date":245,"type":35},"2024-09-27",{"date":247,"type":20},"2034-09",{"name":249,"class":42},"Fundación Española de Hematología y Hemoterapía",36,{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":4},"100576868","ripertamab-plus-eltrombopag-vs-eltrombopag-in-itp-patients-post-steroid-failure-100576868","NCT06790888","Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure","A Multicenter, Randomized Controlled, Open-Label Study of Ripertamab Combined With Eltrombopag Versus Eltrombopag for ITP Patients After First-Line Steroid Therapy","RPE-ITP","Inclusion Criteria:\n\n1. Diagnosis: Confirmed Primary Immune Thrombocytopenia (ITP) with an age range of 18 to 80 years, inclusive, and no gender restrictions.\n2. Bone Marrow Cytology: Diagnosis via bone marrow cytology excluding secondary thrombocytopenia caused by other diseases, with primary ITP patients who are unresponsive to or have relapsed after first-line steroid therapy (platelet count drops below 30×10\\^9\u002FL).\n3. Coagulation Status: Laboratory tests show prothrombin time (PT\u002FINR) and activated partial thromboplastin time (APTT) not exceeding 20% above the upper limit of normal values, with no history of coagulation disorders other than ITP.\n4. Bone Marrow Function: Normal bone marrow function indicated by an absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL and hemoglobin (Hb) ≥90 g\u002FL.\n\nLiver and Kidney Function: Normal liver and kidney function with serum direct bilirubin and indirect bilirubin ≤1.5 times the upper limit of normal (ULN); 5.alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN); serum creatinine ≤1.5 times the upper limit of normal (ULN).\n\n6.Psychiatric History: No history of psychiatric disorders. 7.Informed Consent: Voluntary signing of an informed consent form.\n\nExclusion Criteria:\n\n1. Life-Threatening Bleeding: Presence of bleeding that poses an immediate threat to life, such as severe anemia or central nervous system bleeding.\n2. Recent Treatment: Use of intravenous immunoglobulin, thrombopoietin receptor agonists, recombinant human thrombopoietin (rhTPO), immunosuppressants, anti-CD20 monoclonal antibodies, or systemic corticosteroids within 28 days prior to enrollment.\n3. Malignancy History: History of malignancy.\n4. Cardiac Conditions: Presence of severe heart failure or other diseases significantly impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension, arrhythmias, or prolonged QTc interval within the last 3 months).\n5. Coagulation Disorders: History of coagulation disorders other than ITP, such as disseminated intravascular coagulation (DIC), hemolytic uremic syndrome (HUS), or thrombotic thrombocytopenic purpura (TTPP).\n6. Viral Markers: Hepatitis C virus (HCV) antibody positive with HCV RNA quantitative test ≥10\\^4 copies\u002FmL; or Hepatitis B virus (HBV) markers positive for HBsAg and\u002For HBcAb with HBV DNA positivity.\n7. Immunocompromised: History of immunodeficiency, including HIV positivity or other acquired or congenital immunodeficiency diseases, autoimmune diseases, or a history of organ transplantation.\n8. Tuberculosis: Suspected active or latent tuberculosis.\n9. Active Infections: Presence of active infections at enrollment, or any significant infectious events within 4 weeks prior to enrollment or major surgery within 4 weeks.\n10. Pregnancy and Lactation: Pregnant or nursing women, or women of childbearing potential or considering pregnancy during the study period.\n11. Other Conditions: Any other conditions deemed by the investigator as contraindications for study participation.","80 Years",{"count":261,"type":20},78,[191],"This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed after first-line steroid therapy. Participants will be randomly assigned to one of two treatment groups and followed for 52 weeks to assess response rates and safety.",[26],[266],"Ripertamab","2025-01-19",{"date":269,"type":35},"2025-01-24",{"date":271,"type":20},"2025-02",{"date":273,"type":20},"2027-12",{"name":275,"class":42},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":283,"maxAge":140,"enrollmentInfo":284,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":288,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":182},"100543162","phase-1-efficacy-and-safety-of-car-t-cells-therapy-for-chronic-or-refractory-primary-immune-thrombocytopenia-itp-100543162","NCT06352281","Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)","An Investigator-initiated Trial to Evaluate the Efficacy and Safety of CAR-T Cells Therapy in the Treatment of Chronic or Refractory Primary Immune Thrombocytopenia (ITP)","Inclusion Criteria:\n\n1. Willingness to complete the informed consent process and to comply with study procedures and visit schedule;\n2. Men and women aged 8-75;\n3. Participants diagnosed with chronic (\\>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP;\n4. The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP;\n5. Platelet count \\\u003C30 x 109 \u002F L;\n6. If the patient is taking corticosteroids, the treatment regimen\u002Fdose should be stable (at least 2 weeks prior to screening);\n7. The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant;\n8. Willingness to use effective and reliable methods of contraception throughout the entire study period;\n\nExclusion Criteria:\n\n1. All subjects with diseases which may cause secondary immune thrombocytopenia\n2. Patients with preventive splenectomy;\n3. Hemostatic disorders other than chronic thrombocytopenia;\n4. Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and\u002For NSAIDs) or anti-coagulants for \\> 3 consecutive days within 2 weeks of the study start and until the end of the study;\n5. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts;\n6. Concurrent malignant disease and\u002For history of cancer treatment with cytotoxic chemotherapy and\u002For radiotherapy;\n7. Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment;\n8. History of thrombosis or presence of significant risk factors for thrombosis;\n9. Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system;\n10. Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal);\n11. Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex;\n12. Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study;\n13. Human immunodeficiency virus (HIV) seropositivity, Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive, Patients with hepatitis C (HCV-RNA quantitative test results positive), Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections;\n14. Patients with severe history of allergy or allergic constitution;\n15. Pregnancy and lactation;\n16. History of mental illness and known alcohol\u002Fdrug addiction;\n17. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan;\n18. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;","8 Years",{"count":108,"type":20},[53,23],"It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).",[26],[64,96],"2024-07-18",{"date":291,"type":35},"2024-07-22",{"date":293,"type":35},"2024-02-01",{"date":295,"type":20},"2027-12-31",{"name":297,"class":42},"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":305,"targetDuration":4,"studyType":213,"phases":4,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100526619","thrombopoietin-agonists-in-patients-with-idiopathic-thrombocytopenic-purpura-100526619","NCT06137105","Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura","A Study of Treatment With Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura","Inclusion Criteria:\n\n* Patients presented with Idiopathic thrombocytopenic purpura (ITP)\n\n  1. patients above age of 18 years.\n\nExclusion Criteria:\n\n* patients below age of 18 years .",{"count":19,"type":20},"1. Assesement of response to Thrombopoietin receptor agonists (TPO-RAs) as treatment in Idiopathic thrombocytopenia purpura patients in Assiut University hospital.\n2. Explore side effects of Thrombopoietin receptor agonists in Idiopathic thrombocytopenia purpura .\n3. To study effect of thrombopoietin receptor agonists and Quality life in Idiopathic thrombocytopenia purpura patients.",[26],"2023-11-16",{"date":310,"type":35},"2023-11-18",{"date":312,"type":20},"2023-12-01",{"date":314,"type":20},"2026-12",{"name":316,"class":42},"Assiut University"]